{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:14:45Z","timestamp":1722885285505},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2003,1,20]],"date-time":"2003-01-20T00:00:00Z","timestamp":1043020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The knowledge that drugs can affect renal function is mainly based on experimental studies or case reports. Thus, it has only been investigated in selected populations. Here we describe drug groups associated with altered renal function in the general population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To study this, we used baseline data of 8592 subjects of a population\u2010based cohort. Hyper\u2010 and hypofiltration were defined as a filtration above or below the 90% confidence interval of age\u2010and\u2010sex\u2010corrected creatinine clearance. Drug use was measured in the year preceding the kidney function measurement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence of hyperfiltration (4.6% in the general population) was higher among subjects using anti\u2010diabetics (11.7%), dermatological corticosteroids (5.9%) and sex hormones (5.8%), but lower in subjects using anti\u2010thrombotics (2.4%) and diuretics (2.1%). Hypofiltration (4.3% in the general population) was seen more often in users of beta blockers (6.2%), ACE inhibitors (7.1%), statins (7.2%), anti\u2010thrombitics (6.8%), trimethoprim (7.9%), vaccines (9.4%), NSAIDs (5.2%), anti\u2010ulcer agents (6.3%), laxatives (7.7%) and eyedrops (6.7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Several drug groups found in this overview were to be expected, since patients with kidney diseases often use them (e.g. cardiovascular drugs). Several other drug groups were somewhat unexpected and deserve further attention. Copyright \u00a9 2003 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.811","type":"journal-article","created":{"date-parts":[[2003,2,19]],"date-time":"2003-02-19T09:16:13Z","timestamp":1045646173000},"page":"135-143","source":"Crossref","is-referenced-by-count":5,"title":["Drug\u2010induced renal function impairment: a population\u2010based survey"],"prefix":"10.1002","volume":"12","author":[{"given":"Taco B. M.","family":"Monster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lolkje T. W.","family":"de Jong\u2010van den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the PREVEND Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,2,18]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-015-9088-4"},{"key":"e_1_2_1_3_2","first-page":"339","volume-title":"Davies's Textbook of Adverse Drug Reactions","author":"Swanepoel CR","year":"1998"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00869.x"},{"issue":"2","key":"e_1_2_1_5_2","first-page":"140","article-title":"Drug\u2010induced renal toxicity: diagnosis and prevention","volume":"59","author":"Farrugia E","year":"1998","journal-title":"Hosp Med"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199816121-00035"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)93251-6"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004670200009"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.060002804.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.244.4.360"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)90846-8"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1990.tb03487.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90450-7"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.1.190"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000184985"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.301.6755.818-b"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1992.tb121517.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(96)90569-7"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.suppl_5.11"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.12.1900"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022009701"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.8.1118"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1981.241.1.F85"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)70184-1"},{"issue":"10","key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1681\/ASN.V11101882","article-title":"Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population","volume":"11","author":"Pinto\u2010Sietsma S\u2010J","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.722"},{"volume-title":"ATC Index With DDDs 2001","year":"2001","author":"WHO Collaborating Centre for Drug Statistics Methodology","key":"e_1_2_1_27_2"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000185747"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.33.1.90"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.811","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T20:02:21Z","timestamp":1696622541000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,18]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1002\/pds.811"],"URL":"https:\/\/doi.org\/10.1002\/pds.811","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2003,2,18]]}}}